The progressive production and subsequent accumulation of β-amyloid (Aβ), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimer's Disease (AD). Aβ is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of Ap culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains. In this review we report the known structural features of amyloid peptides and fibrils, and we give an overview of all small molecules that have been found to interact with Aβ aggregation. Deeper knowledge of the mechanism leading to amyloid fibrils along with their molecular structure and the molecular interactions responsible for activity of small molecules could supply useful information for the design of new AD therapeutic agents

Re, F., Airoldi, C., Zona, C., Quattrocchi, N., LA FERLA, B., Nicotra, F., et al. (2010). Beta Amyloid Aggregation Inhibitors: Small Molecules as Candidate Drugs for Therapy of Alzheimer Disease. CURRENT MEDICINAL CHEMISTRY, 17(27), 2990-3006 [10.2174/092986710791959729].

Beta Amyloid Aggregation Inhibitors: Small Molecules as Candidate Drugs for Therapy of Alzheimer Disease

RE, FRANCESCA;AIROLDI, CRISTINA;ZONA, CRISTIANO;QUATTROCCHI, NICOLETTA;LA FERLA, BARBARA;NICOTRA, FRANCESCO;MASSERINI, MASSIMO ERNESTO
2010

Abstract

The progressive production and subsequent accumulation of β-amyloid (Aβ), a proteolytic fragment of the membrane-associated amyloid precursor protein (APP), plays a central role in Alzheimer's Disease (AD). Aβ is released in a soluble form that may be responsible for cognitive dysfunction in the early stages of the disease, then progressively forms oligomeric, multimeric and fibrillar aggregates, triggering neurodegeneration. Eventually, the aggregation and accumulation of Ap culminates with the formation of extracellular plaques, one of the morphological hallmarks of the disease, detectable post-mortem in AD brains. In this review we report the known structural features of amyloid peptides and fibrils, and we give an overview of all small molecules that have been found to interact with Aβ aggregation. Deeper knowledge of the mechanism leading to amyloid fibrils along with their molecular structure and the molecular interactions responsible for activity of small molecules could supply useful information for the design of new AD therapeutic agents
Articolo in rivista - Articolo scientifico
β-amyloid; Aggregation inhibitors; Alzheimer's disease
English
2010
17
27
2990
3006
none
Re, F., Airoldi, C., Zona, C., Quattrocchi, N., LA FERLA, B., Nicotra, F., et al. (2010). Beta Amyloid Aggregation Inhibitors: Small Molecules as Candidate Drugs for Therapy of Alzheimer Disease. CURRENT MEDICINAL CHEMISTRY, 17(27), 2990-3006 [10.2174/092986710791959729].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/17035
Citazioni
  • Scopus 116
  • ???jsp.display-item.citation.isi??? 112
Social impact